Bristol Vanlev OCTAVE Trial Will Compare Angioedema To ACE Inhibitors
Executive Summary
Bristol's effort to resurrect the Vanlev NDA via the 25,000-patient OCTAVE trial will produce "the best look at angioedema for ACE inhibitors that has ever been compiled," Bristol VP-Corporate Development for the Worldwide Medicines Group Andrew Bodnar, MD, told a July 20 quarterly earnings conference call.
You may also be interested in...
Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
Bristol Vanlev
Omapatrilat OCTAVE hypertension study analysis is expected in late summer or early fall, Bristol says, following company's decision to maintain blinding until all patients have completed the 24 weeks of treatment. In July, the company projected that the data would be available for analysis by late in the second quarter (1"The Pink Sheet" July 31, 2000, p. 21)
Bristol Vanlev
Omapatrilat OCTAVE hypertension study analysis is expected in late summer or early fall, Bristol says, following company's decision to maintain blinding until all patients have completed the 24 weeks of treatment. In July, the company projected that the data would be available for analysis by late in the second quarter (1"The Pink Sheet" July 31, 2000, p. 21)